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Abstract
 
Lipopolysaccharide (LPS) is lethal to animals because it activates cytokine release, causing septic
shock and tissue injury. Early proinflammatory cytokines (e.g., tumor necrosis factor [TNF]
and interleukin [IL]-1) released within the first few hours of endotoxemia stimulate mediator
cascades that persist for days and can lead to death. High mobility group 1 protein (HMG-1), a
ubiquitous DNA-binding protein, was recently identified as a “late” mediator of endotoxin le-
thality. Anti–HMG-1 antibodies neutralized the delayed increase in serum HMG-1, and pro-
tected against endotoxin lethality, even when passive immunization was delayed until after the
early cytokine response. Here we examined whether HMG-1 might stimulate cytokine syn-
thesis in human peripheral blood mononuclear cell cultures. Addition of purified recombinant
 
HMG-1 to human monocyte cultures significantly stimulated the release of TNF, IL-1
 
a
 
, IL-
1
 
b
 
, IL-1RA, IL-6, IL-8, macrophage inflammatory protein (MIP)-1
 
a
 
, and MIP-1
 
b
 
; but not
IL-10 or IL-12. HMG-1 concentrations that activated monocytes were within the pathological
range previously observed in endotoxemic animals, and in serum obtained from septic patients.
HMG-1 failed to stimulate cytokine release in lymphocytes, indicating that cellular stimulation
was specific. Cytokine release after HMG-1 stimulation was delayed and biphasic compared
with LPS stimulation. Computer-assisted image analysis demonstrated that peak intensity of
HMG-1–induced cellular TNF staining was comparable to that observed after maximal stimu-
lation with LPS. Administration of HMG-1 to Balb/c mice significantly increased serum TNF
levels in vivo. Together, these results indicate that, like other cytokine mediators of endotoxin
lethality (e.g., TNF and IL-1), extracellular HMG-1 is a regulator of monocyte proinflamma-
tory cytokine synthesis.
Key words: HMG-1 • tumor necrosis factor • monocyte activation • septic shock • 
lipopolysaccharide
 
Introduction
 
High mobility group 1 protein (HMG-1), named for its
rapid migration properties on electrophoretic gels, is a
member of the nonhistone chromatin-associated proteins.
 
HMG-1 is translated as a 214–amino acid protein, and
extensively modified posttranslationally, by glycosylation,
acylation, methylation, and phosphorylation (1, 2). The
primary structure is evolutionarily conserved, with 100%
amino acid sequence homology between rat and mouse,
and 99% homology between rodents and humans (3, 4).
HMG-1 is dipolar, bearing an acidic COOH terminus with
a 30–amino acid stretch of glutamic and aspartic acid resi-
dues, and at least two basic structural units termed HMG
domains (5). Intracellular HMG-1 has been studied previ-
ously for its roles in binding DNA; stabilizing nucleosome
formation; as a general transcription factor for nucleolar
and mitochondrial RNA polymerases; and as a gene- and
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tissue-specific transcriptional regulator that can enhance
transcription and/or replication (5–10).
Extracellular HMG-1 was recently implicated as a “late”
mediator of delayed endotoxin lethality, because murine
and human macrophages/monocytes release large amounts
of a 30-kD form of HMG-1 when stimulated by exposure
to bacterial endotoxin (11). During lethal endotoxemia in
mice, serum HMG-1 levels accumulated 16–36 h after LPS
administration (11). Passive immunization of mice with
anti–HMG-1 antibodies attenuated LPS-induced lethality,
even when antibody administration was delayed until after
the onset of the early proinflammatory cytokine response
(2 h after endotoxin administration). Purified rHMG-1 was
lethal to both LPS-responsive (C3H/HeN, Balb/c) and
LPS-resistant (C3H/HeJ) mice, indicating that HMG-1
mediates lethal toxicity in the absence of LPS signal trans-
duction (11). HMG-1 levels were increased significantly in
critically ill patients with sepsis: the highest serum HMG-1
levels were observed in patients that succumbed (11).
HMG-1 levels were also significantly increased in the se-
rum of an uninfected patient with hemorrhagic shock, sug-
gesting that extracellular HMG-1 might play a mediator
role in the setting of inadequate tissue perfusion (12).
Recently, we observed that toxic doses of HMG-1 were
associated with the development of fever, weight loss, pilo-
erection, shivering, and microthrombi formation in the
lungs and liver (11). Other proinflammatory mediators of
endotoxemia that mediate similar pathological effects (e.g.,
TNF and IL-1) also function as potent stimulators of
monocyte cytokine release in order to amplify and extend
the “cytokine cascade” (13–17). Accordingly, we consid-
ered it plausible that HMG-1 might also function to stimu-
late monocytes to release TNF and other proinflammatory
cytokines. We tested this hypothesis in cultured monocytes
and macrophages.
 
Materials and Methods
 
Reagents.
 
Rat rHMG-1 was expressed in 
 
Escherichia coli
 
 and
purified to homogeneity as described previously (11). rHMG-1
preparations were tested routinely for LPS content by the chro-
mogenic 
 
Limulus
 
 amebocyte lysate assay (Endochrome; Charles
River); preparations contained 600 pg or less of endotoxin per
microgram of rHMG-1.
 
Blood Donors and Cell Cultures.
 
PBMCs were isolated by en-
dotoxin-free Ficoll-Paque™ PLUS centrifugation (Amersham
Pharmacia Biotech) from buffy coats obtained from healthy adult
blood donors at the Karolinska Hospital. The PBMCs were cul-
tured at a cell concentration of 10
 
6
 
 cells/ml in RPMI 1640 me-
dium (GIBCO BRL) supplemented with 5% heat-inactivated hu-
man AB serum.The cells were cultured alone or in the presence
of indicated concentrations of rHMG-1 or LPS (
 
E. coli
 
 055:B5,
Department of Bacteriology, Karolinska Institutet) or rTNF
(NordicBioSite). Cultures were supplemented routinely with
polymyxin B (10 
 
m
 
g/ml, 70 U/ml, Polymyxin B Sulphate;
Sigma-Aldrich) to inhibit contaminating endotoxin. The poly-
myxin B dose was determined from separate experiments to neu-
tralize a concentration of 100 ng/ml of LPS from 
 
E. coli
 
 055:B5;
this polymyxin B dose was neither toxic nor stimulating for cy-
 
tokine production in control experiments with rTNF-
 
a
 
 and hu-
man PBMCs (data not shown).
 
Trypsin Digestion of HMG-1.
 
A solution of purified recombi-
nant HMG-1 (200 
 
m
 
g/ml, in PBS) was mixed with one volume
of type I bovine trypsin (2 
 
m
 
g/ml, cat. no. T8003; Sigma-Aldrich)
and incubated at 20
 
8
 
C for 12 h. Degradation was confirmed by
electrophoresis on a 4–20% SDS-polyacrylamide gel. The degraded
rHMG-1 was added to the cultures of human PBMCs, and TNF
released into the conditioned supernatant was determined by
ELISA.
 
TNF ELISA.
 
Purified rHMG-1 was administered intraperi-
toneally into Balb/c mice (male, 6–7 wk, 20–23 g) at indicated
doses, and serum was collected 6 h later. TNF levels were deter-
mined by ELISA (R&D Systems). TNF released by human mono-
cytes was determined using another human-specific TNF ELISA.
 
TNF Production in C3H/HeJ Cultured Macrophages.
 
Resident
peritoneal macrophages were obtained by peritoneal lavage with
5 ml Hepes-buffered RPMI in C3H/HeJ mice. The macrophages
were then cultured for 2 h with indicated doses of rHMG-1 or
vehicle in DMEM (cat. no. 31331-028; GIBCO BRL
 
) 
 
supple-
mented with 10% fetal bovine serum in pyrogene-free 48-well
flat-bottomed cell culture plates (Costar Corp.).
 
RNase Protection Assay.
 
Human PBMCs tested for TNF
mRNA expression were cultured in OPTI-MEM I medium.
Total RNA was extracted from cells using RNAzol B reagent
following the manufacturer’s instructions (Tel-Test “B”, Inc.)
and electrophoresed on 1.2% agarose/17% formaldehyde gel to
verify RNA integrity. The levels of TNF-
 
a
 
 (287 bp) and glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) mRNA (97 bp)
were measured using an RNase Protection assay kit (cat. no.
hck3; BD PharMingen). The antisense RNA probes were labeled
with [
 
a
 
-
 
32
 
P]UTP (800 
 
m
 
Ci/mMol; Amersham Pharmacia Bio-
tech) using T7 RNA polymerase. Relative RNA levels were
quantified with an Instant Imager (Packard Instruments).
 
Antibodies.
 
Antibodies specific to cytokines were used for in-
direct immunocytochemistry. TNF-
 
a
 
 (AF-210), IL-1
 
a
 
 (AF-200),
IL-1RA (AF-280), IL-6 (AF-206), IL-8 (AF-208), IL-12 (AF-
219), macrophage inflammatory protein (MIP)-1
 
a
 
 (BAF-270),
and MIP-1
 
b
 
 (BAF-271) were antigen affinity-purified goat IgG
antibodies from R&D Systems; TNF-
 
a
 
 (mAb1
 
1
 
mAb11, mouse
IgG1 mAb) was from BD PharMingen, IL-1
 
b
 
 (2.D.8
 
1
 
1437.96-
15 mouse IgG1 mAb) was from Immunokontakt). IL-10
(19.F.1
 
1
 
12.G.8 rat IgG2a mAb; BD PharMingen), and mouse
TNF were detected using goat anti-mTNF (AF-410) from R&D
Systems. The cytokine-specific antibodies were used at a final
concentration of 2–5 
 
m
 
g/ml. Monocytes were identified by an
anti–calprotectin-1 mAb (DAKO-MAC387, mouse IgG1; Dako)
diluted 1:600. Secondary antibodies for immunocytochemistry
included Fab
 
2
 
-fragmented biotinylated donkey anti–goat IgG (cat.
no. 705-066-147; Jackson ImmunoResearch Laboratories) diluted
1:1,000; biotinylated goat anti–mouse IgG
 
1 
 
(cat. no. M32115;
Caltag Laboratories) diluted 1:600; or biotinylated goat anti–rat
IgG (cat. no. BA9400; Vector Laboratories) diluted 1:500.
 
Cytokine Detection by Indirect Immunocytochemistry.
 
Cytokines
were detected in human mononuclear cells using computerized
cell staining techniques that have been described previously (18–
20). Cell-associated cytokines were detected with a three-step
immunostaining procedure using a primary cytokine-specific an-
tibody, a secondary biotinylated cytokine-specific antibody, and a
developing step with Oregon Green–avidin D (cat. no. A6374;
Molecular Probes) for UV microscopy or avidin-biotin–horserad-
ish peroxidase (Vectastain Elite PK-6100; Vector Laboratories)
followed by diaminobenzidine (DAB peroxidase substrate kit SK- 
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4100; Vector Laboratories) for conventional microscopy. Finally,
the cells were counterstained with hematoxylin, washed, dried,
and mounted with buffered glycerol.
 
Computer-assisted Image Analysis for Quantification of Cytokine-
producing Cells.
 
The stained cells were examined on a Polyvar 2
microscope (Reichert-Jung) equipped with a 3CCD color cam-
era (DXC-750P; Sony Corp.) and a monochrome CCD video-
camera for UV light detection (RS-170; Cohu). Images were as-
sessed using software as described previously (Quantimet 550S;
Leica Cambridge Instruments) (18–20).
 
Statistical Analysis.
 
Student’s unpaired 
 
t
 
 test was used to com-
pare differences between HMG-1– and LPS-stimulated cultures.
 
Results
 
HMG-1 Induces TNF Release by Cultured Human PBMCs.
 
TNF is one of the earliest cytokines released by acti-
vated macrophages, and occupies a pivotal role in the
pathogenesis of inflammation, endotoxic shock, and tissue
injury (14, 21). We measured TNF in supernatants condi-
tioned by hPBMCs exposed to rHMG-1 for 4 h, and ob-
served an HMG-1 dose–dependent stimulation of TNF
(Fig. 1). HMG-1 concentrations as low as 10 ng/ml signifi-
cantly increased TNF release. This TNF-stimulating effect
of HMG-1 was observed even in the presence of polymyxin
B at concentrations neutralizing 
 
.
 
100-fold the amount of
contaminating LPS. Proteolytic degradation of HMG-1
with trypsin eliminated the TNF-stimulating activity of
rHMG-1 (data not shown), indicating that the induction of
 
increased TNF synthesis by HMG-1 requires intact rHMG-1.
In contrast, trypsinization of endotoxin did not destroy
the TNF-stimulating activity of endotoxin (not shown),
giving additional evidence that HMG-1 specifically medi-
ated TNF release. To fully exclude the possibility that the
insignificant amounts of LPS present in the experimen-
tal conditions mediated the TNF-stimulating effects of
HMG-1, we added HMG-1 as a stimulating agent to pri-
mary peritoneal macrophages derived from C3H/HeJ mice.
These mice are resistant to endotoxin signal transduction be-
cause of a mutation in the TLR4 endotoxin receptor (22).
TNF synthesis in C3H/HeJ macrophages was increased sig-
nificantly by addition of rHMG-1 (Table I), indicating that
HMG-1 activation of cytokine synthesis in macrophages/
monocytes occurs independently of LPS signal transduction.
 
HMG-1 Stimulates Increased Expression of TNF mRNA in
Human PBMCs.
 
To address the molecular basis of HMG-
1–induced monocyte activation, we measured TNF
mRNA levels in HMG-1–stimulated human PBMCs. Re-
sults obtained by an RNase Protection assay demonstrated
that stimulation with rHMG-1 significantly induced TNF
mRNA production in a time-dependent manner (Fig. 1
B). Upregulation was observed within 4 h after rHMG-1
addition, but peak TNF mRNA levels were not reached
until 10 h and remained elevated for at least 22 h. This
TNF mRNA kinetic profile differs significantly from that
observed after LPS stimulation, in which peak TNF
mRNA levels occurred within 1 or 2 h.
Figure 1. (A) HMG-1 stimulates release of TNF from cultured human
PBMCs.  Ficoll-separated human PBMCs were stimulated with purified
rHMG-1 (0.001–1 mg/ml) in the presence of polymyxin B (10 mg/ml), and
the supernatant was assayed for TNF by ELISA 4 h after stimulation. Data
represent mean 6 SEM of two separate experiments (in triplicate). (B)
HMG-1 induces increased expression of TNF mRNA in human PBMCs.
Human PBMCs were cultured in OPTI-MEM I medium with rHMG-1 (1
mg/ml) and polymyxin B (10 mg/ml). Cells were harvested at the indicated
time points and assayed for TNF mRNA and GAPDH mRNA levels in con-
trols by RNase Protection assay. Data are representative of two independent
experiments. (C) Phenotypic characterization of TNF-producing PBMCs
stimulated with HMG-1. Typical localization of intracellular TNF accumula-
tion demonstrated by indirect immunofluorescence (A, Oregon Green) 8 h
after HMG-1 stimulation. The same cells were stained with rhodamine for a
monocytic marker (B, calprotectin 1). (D) Intracellular TNF expression after HMG-1 stimulation of PBMCs. Human PBMCs were cultured alone or
with HMG-1 (1 mg/ml) in the presence of polymyxin B or LPS (100 ng/ml). The cells were harvested at the indicated time points, fixed, and stained for
TNF using indirect immunofluorescence. Only monocytes contributed to the TNF formation as judged by morphology and two-color staining. The re-
sults are expressed as frequency of TNF-producing cells in the monocyte population. Data represent mean 6 SEM of three separate experiments (in du-
plicate). *P , 0.05 vs. LPS stimulation. 
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HMG-1 Stimulation of Intracellular TNF Synthesis in Hu-
man PBMCs Is Delayed and Biphasic Compared with LPS.
 
To characterize the cell type responding to HMG-1, and
the kinetics of newly synthesized TNF in individual cells,
we performed two-color immunofluorescent staining of
PBMCs using TNF-specific and monocyte-specific (anti–
calprotectin-1) antibodies (Fig. 1 C). As shown previously,
addition of LPS alone to the PBMC cultures activated
TNF synthesis in nearly 40% of monocytes within 1 h as
judged by morphology and two-color staining (Fig. 1 D).
Stimulation of PBMCs by HMG-1 also caused a significant
increase in cell-associated TNF synthesis that was restricted
to monocytes; TNF synthesis was not increased in lympho-
cytes after exposure to HMG-1. The kinetic pattern of
HMG-1–induced TNF synthesis differed significantly
compared with LPS-induced cells (Fig. 1 D, and Fig. 2).
HMG-1–activated TNF synthesis occurred in a biphasic
pattern, with an early peak at 3 h after addition of HMG-1,
followed by another peak after 8–10 h. The percentage of
 
TNF-producing cells during the early peak after HMG-1
stimulation was significantly smaller compared with LPS
stimulation. HMG-1 stimulation activated a significantly
higher number of TNF-producing monocytes during the
later peak (Fig. 1 D), which was surprising because the re-
lease of HMG-1 itself is delayed after endotoxin adminis-
tration (11). Thus, this late mediator of endotoxin lethality
is also a monocyte-activating cytokine that stimulates a de-
layed release of TNF.
In separate dose–response studies, we observed that
HMG-1 concentrations that significantly increased TNF
release by PBMCs (Fig. 1 A) also significantly upregulated
the number of TNF-producing monocytes. Computer-
assisted image analysis of these cultures revealed that after 8 h
of stimulation with HMG-1 the intensity of individual cells
staining positive for TNF compared favorably with the
peak staining intensity induced by LPS stimulation for 1 h
(not shown).
 
Administration of HMG-1 to Mice Stimulates Increased Se-
rum TNF.
 
These results strongly implicated HMG-1 as a
stimulus for TNF synthesis and release. Our earlier work
indicated that high levels of HMG-1 are found in the serum
of endotoxemic mice and septic humans (11). To determine
whether HMG-1 can also stimulate TNF synthesis in vivo
 
,
 
we administered purified rHMG-1 to Balb/c mice and
measured serum TNF by ELISA. Administration of suble-
thal doses of HMG-1 (10 or 100 
 
m
 
g) to mice significantly
stimulated the appearance of TNF in the serum within 6 h
(Fig. 3), indicating that systemic exposure to sublethal doses
of HMG-1 activates systemic TNF release in vivo.
 
HMG-1 Stimulates the Synthesis of Proinflammatory Cyto-
kines and Chemokines in Human PBMCs.
 
To determine
whether the induction of monocyte-derived cytokines by
HMG-1 is specific to TNF, we measured the production of
IL-1
 
a
 
, IL-1
 
b
 
, IL-1RA, IL-6, IL-8, IL-10, MIP-1
 
a
 
, and
MIP-1
 
b
 
 in HMG-1–stimulated PBMCs (Fig. 4). Interest-
ingly, the inducible cytokine response to HMG-1 was totally
confined to the monocyte population as revealed by immu-
 
Table I.
 
HMG-1 Activates Cytokine Synthesis in
C3H/HeJ Macrophages
 
[HMG-1] TNF-producing cells
 
m
 
g/ml %
 
0 0.5
1 5.8
10 19.2
100 4.8
Resident peritoneal macrophages were obtained by peritoneal lavage
from C3H/HeJ mice, and cultured for 2 h with rHMG-1 or vehicle in
the doses shown. Cells were harvested, fixed on adhesive glass slides, and
stained for intracellular TNF using indirect immunofluorescence.
Results are based on means of 2,000 counted macrophages on each
microscopy slide (in duplicate).
Figure 2. TNF expression in HMG-1–stimulated human
PBMCs. Human PBMCs were cultured alone or with either
rHMG-1 (1 mg/ml) or LPS (100 ng/ml) (1 or 8 h), then
stained for intracellular TNF. TNF-producing monocytes
are revealed with an intracellular, round brown dot, repre-
senting an accumulation of TNF in the Golgi organelle of
producer cells. The number of TNF-expressing monocytes
in the LPS-stimulated cultures was increased significantly
within 1 h compared with HMG-1–stimulated or unstimu-
lated cultures. In contrast, HMG-1 stimulation significantly
increased TNF expression at 8 h. No TNF was detected in
unstimulated cells. Note pronounced monocyte aggregation
after 8 h of culture. 
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nohistochemistry. HMG-1 significantly activated the synthe-
sis of all cytokines assayed, with the exception of the antiin-
flammatory cytokine IL-10 (Fig. 4) and the proinflammatory
cytokine IL-12 (not shown). The frequency of proinflam-
matory cytokine– or chemokine-producing monocytes was
remarkably similar after HMG-1 or LPS stimulation, except
that the induction of cytokine synthesis was delayed by 1–4 h
in the HMG-1–treated cultures compared with LPS. How-
ever, there was no delay in the upregulation of the antiin-
flammatory cytokines IL-1RA and IL-10 (Fig. 4). HMG-1
stimulation of both IL-6 and TNF was biphasic.
 
Discussion
 
These results demonstrate for the first time that HMG-1
acts as a cytokine that specifically stimulates cytokine syn-
thesis in human monocytes. Macrophages and monocytes
occupy a central role in coordinating the immune response
to injury and infection. The observation that HMG-1, a
mediator of late endotoxin lethality, can activate additional
downstream cytokine cascades has widespread implications,
especially because HMG-1 is nearly as potent as LPS in
stimulating monocyte cytokine synthesis.
Our findings also indicate that monocytes, but not lym-
phocytes, are cellular targets for the cytokine-inducing ac-
tivity of HMG-1. We have previously reported that LPS,
TNF, or IL-1 can stimulate the production of HMG-1 by
monocytes (11). The present study extends these findings,
and importantly reveals a reciprocal functional relationship
between the activities of the early (TNF and IL-1) and late
(HMG-1) cytokines. It is now apparent that HMG-1 can
participate in “cross-talk” for the propagation and amplifi-
cation of downstream proinflammatory responses. Here we
used three independent cytokine detection assays to con-
firm the production of TNF after HMG-1 exposure in
vitro (Figs. 1 and 2) or in vivo (Fig. 3). TNF synthesis was
readily demonstrated at the mRNA level (Fig. 1 B) and at
the protein level both intracellularly (Fig. 1, C and D, and
Fig. 2) and extracellularly (Fig. 1 A and Fig. 3). The com-
puter-assisted image analysis to detect intracellular TNF of-
fered a significant advantage over flow cytometry analysis.
The latter method would have grossly underestimated the
magnitude of TNF produced, which mainly occurred in
aggregates of activated monocytes (Fig. 2), routinely gated
out by the flow cytometer.
HMG-1 was previously implicated as a ligand for the
monocyte receptors for advanced glycated proteins (RAGE)
(23, 24). RAGE receptor–ligand interaction with glycated
proteins can indeed activate macrophages (25), and radiola-
beled HMG-1 binds specifically to human monocytes
(Yang, H., and K.J. Tracey, unpublished observations), but
it is presently unknown whether HMG-1 bound to RAGE
mediates cytokine synthesis. It remains theoretically possible
that HMG-1 activation of monocytes may also occur via re-
ceptor-independent pathways. For instance, HMG-1 signif-
icantly increases cellular uptake of DNA (26), and bacterial
DNA containing CpG motifs that activate monocyte cyto-
kine synthesis are ubiquitous during infection (27). Our
observations that HMG-1 stimulates monocytes but not
lymphocytes to produce cytokines indicate that the proin-
flammatory role of HMG-1 is cell type specific.
Cytokines are defined as proteins released from activated
immunocytes that influence diverse metabolic or immuno-
logical response in other cells (28). It is now clear that as a
cytokine, extracellular HMG-1 occupies a unique position
in the proinflammatory mediator cascade. Clinical reports
indicated that increased levels of antibodies against HMG-1
can be found in patients with autoimmune diseases (29,
30), and that HMG-1 levels are increased in patients with
sepsis or hemorrhagic shock (11, 12). HMG-1 has been
termed a late mediator of endotoxin lethality, because its
release is delayed by several hours compared with other
proinflammatory cytokines that mediate shock and tissue
injury (11). Once released, however, HMG-1 is a potent
Figure 3. Administration of HMG-1
in vivo stimulates increased serum TNF
in mice. Balb/c mice received an intra-
peritoneal injection of rHMG-1 in the
doses indicated; blood was obtained af-
ter 6 h and serum was analyzed for TNF
by ELISA (means 6 SEM, n 5 3).
Figure 4. HMG-1 stimulates the expression of cytokines and chemo-
kines in human PBMCs.  Human PBMCs were cultured with either
rHMG-1 (1 mg/ml) plus polymyxin B (10 mg/ml) or LPS alone (100 ng/
ml). Cells were harvested in longitudinal studies, fixed, and stained using
indirect immunofluorescence. Monocytes were the only cells contribut-
ing to the synthesis of the studied mediators, confirmed by two-color
staining. *P , 0.05 vs. LPS. 
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activator of monocyte cytokine synthesis that mediates a
delayed and prolonged phase of monocyte activation.
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